Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

How much potential does "AI+" hold for the pharmaceutical industry? HealthGen partners with Tencent Quantum Lab to explore synthetic biology research and development.

Published Time:

2023-03-31

Recently, the "AI+" concept has continued to ferment, with AI continuously empowering various industries, and the pharmaceutical and medical fields have also been catalyzed. Securities firms have shown a significant increase in attention to synthetic biology. CICC (600030 ) pointed out that synthetic biology is one of the most noteworthy industries of the 21st century, and synthetic biology technology is rapidly developing towards practical application and industrialization.

In the pharmaceutical field, the application of synthetic biology mainly involves two aspects: the synthesis of drug intermediates/active pharmaceutical ingredients and the use of artificially modified organisms for diagnosis and treatment. In the area of drug intermediates/active pharmaceutical ingredients, synthetic biology methods can reduce costs and alleviate the shortage of some drugs caused by the scarcity of related plants.

At the end of 2020, HealthGen (600380 ) Pharmaceutical Group and Lizhu Group (000513 ) jointly established the HealthGen Biopharmaceutical Research Institute, committed to using advanced synthetic biology methods, through microbial genome mining, using natural or artificial biological components to design, modify, and de novo synthesize the genetic material of microorganisms and other living organisms, combining fermentation metabolic engineering and protein directed evolution methods to construct efficient cell factories.

In 2021, HealthGen Biopharmaceutical Research Institute signed a strategic cooperation agreement with Tencent Quantum Laboratory. The research institutions of these two giants joined forces across industries to jointly promote the application of quantum computing + artificial intelligence in microbial synthetic biology research and related drug research, promoting the development and progress of pharmaceutical R&D technology. This also marks that HealthGen and Lizhu Group have seized the first-mover advantage in the layout of synthetic biology.

In 2022, new progress was announced on the cooperation project between HealthGen and Tencent Quantum Laboratory. The two have jointly developed a deep learning-based algorithm architecture for predicting potential biosynthetic gene clusters (BGCs) and have jointly applied for 1 national invention patent.

From the perspective of the industrial chain, the synthetic biology industry can be divided into three parts: upstream, midstream, and downstream, representing the tool type, platform type, and application type, respectively. Upstream tool companies mainly focus on the research of basic technical tools such as DNA synthesis; midstream platform companies focus on synthetic plasmids and microorganisms or provide synthetic biology platform design schemes; downstream application companies focus on the practical application of synthetic biology technology. According to CICC research report shows that HealthGen is a representative of application-type pharmaceutical raw material companies, and its subsidiary Lizhu Group is a representative of tool-type DNA/RNA editing and synthesis companies.

 

Transferred from: Financial World